Article begins on page three of this document.

Title	A case of drug reaction with eosinophilia and systemic symptoms (DRESS) without a typical precipitant
-------	---

Authors:

	Title	First name	Mid inits	Last name	Postnom (eg, PhD) [3 only for publication]	Position1	Address1	Position2	Address2	Tel	Email
1	Dr.	David	WJ	Griffin	BBiomedSci, BSc (Hons), MBBS (Hons), MPH		1			(03) 9076 2000	davidwjgriffin@gmail.com
2	Dr.	Genevieve	E	Martin	MBBS (Hons), BMedSc (Hons), DPhil		1			(03) 9076 2000	g.martin@alfred.org.au
3	Prof.	Catriona		McLean	AO, FAHMS, FRCPA, BSc, MBBS, MD, FFSc	Head of Department	1			03 9076 3150	c.mclean@alfred.org.au
4	Prof.	Allen	C	Cheng	MBBS, FRACP, MPH, PhD	Professor of Infectious Diseases Epidemiology and Director of the Infection Prevention and Healthcare Epidemiology Unit	1		2	0418 818 129	allen.cheng@monash.edu
5	Dr.	Michelle	L	Giles	MBBS, FRACP, PhD	Infectious Diseases Physician	1		2	03 9076 6080	m.giles@alfred.org.au
6											

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as [doi: 10.1002/MJA2.50519](https://doi.org/10.1002/MJA2.50519)

This article is protected by copyright. All rights reserved

Number of corresponding author:	2
Number of alternative corresponding author:	

Addresses:

	Institution		City	State	Post Code	
1	Alfred Health		Melbourne	VIC	3004	
2	Monash University		Melbourne	VIC	3004	
3						
4						
5						

Postal address of first corresponding author (if different from the institutional address given above)

Primary Keywords [Office use only]	Pharmaceutical preparations; Infectious diseases; Environment and public health; Immune system diseases
Secondary keywords [Office use only]	Adverse drug reactions; Influenza; Vaccination; Drug hypersensitivity
Notes:	

Article details (press ctrl – 9 to enter details):

Article type	Medical education
Blurb	

Office use

<i>Ms. Number</i>	mja19.00709. R2
<i>Medical editor</i>	Christine Gee
<i>Medical editor email</i>	cgee@mja.co m.au
<i>Structural editor</i>	Laura Teruel
<i>Structural editor email</i>	lteruel@mja.c

--	--

	om.au
<i>Section/Category</i>	Medical education
<i>Strapheading</i>	Medical education
<i>Substrap</i>	Lessons from practice

Wiley – file data:

Filename for copyediting	mar_mja19.00709_ms.docx
Accompanying graphics	mar_mja19.00709_gr1.jpg, mar_mja19.00709_gr1.tif mar_mja19.00709_gr2.jpg, mar_mja19.00709_gr2.eps mar_mja19.00709_gr3.jpg, mar_mja19.00709_gr3.tif
Stock images	None
Appendices	None

Office use – history:

Event	Date
Original submission received	25/07/2019

Event	Date
Accept	26/09/2019

Proof sent to author	
Proof returned by author	
Published (date format xx/xx/xx)	20/04/20
Issue	7
Vol	212
DOI	10.5694/mja19.00709
Journal	The Medical Journal of Australia
Original article DOI (for response)	

A case of drug reaction with eosinophilia and systemic symptoms (DRESS) without a typical precipitant

Clinical record

An 80-year-old man presented with 2 days of fever and a widespread, itchy, non-blanching, erythematous rash involving more than 50% of body surface area over arms, legs, abdomen, back and palms, with sparing of the face and soles of feet (Box 1). He had a history of type 2 diabetes mellitus (treated with sitagliptin 100 mg and metformin 1000 mg modified release daily), hypertension (perindopril arginine 2.5 mg daily), vitamin D deficiency (weekly colecalciferol 125 µg oral) and pernicious anaemia.

He received an adjuvanted trivalent influenza vaccine (TIV) (Fluad; Seqirus, Australia) for the first time 7 days earlier, having tolerated a quadrivalent influenza vaccine in 2017. He had no localising infective or rheumatological symptoms and no medication changes in the preceding year.

On examination, he was febrile (39.9°C), tachycardic and hypotensive. He had the above described rash and inguinal and axillary lymphadenopathy. There was no mucosal involvement or facial oedema. Further physical examination was unremarkable.

The patient received intravenous fluids, flucloxacillin and ceftriaxone, with a presumptive diagnosis of sepsis. Admission investigations revealed a leucocytosis (29.6×10^9 cells/L; normal range [NR], $2.9\text{--}12.7 \times 10^9$ cells/L) with neutrophilia (28.0×10^9 cells/L; NR, $1.9\text{--}8 \times 10^9$ cells/L) and eosinophilia (0.6×10^9 cells/L; subsequent peak 2.3×10^9 cells/L; NR, $< 5 \times 10^9$ cells/L) (Box 2). There was no lymphocytosis or atypical lymphocytes on blood film. The patient had an acute kidney injury (creatinine 184 µmol/L, baseline 80 µmol/L; NR, 60–110 µmol/L), with bland sediment; liver function was normal. Bacterial cultures of blood and urine were negative. Nasopharyngeal polymerase chain reaction (PCR) was negative for respiratory viruses and *Mycoplasma*. Blood PCR excluded cytomegalovirus, herpes simplex, varicella zoster, and enterovirus and adenoviruses; human herpes virus-6 was not specifically tested. Serology was negative for syphilis, human immunodeficiency virus, and viral hepatitis, and revealed previous parvovirus infection. Vasculitic screening was negative. The result of a skin biopsy is shown in Box 3.

A diagnosis of drug reaction with eosinophilia and systemic symptoms (DRESS) was made (Registry of Severe Cutaneous Adverse Reaction [RegiSCAR] score 6, classified as

definite¹). This was likely triggered by influenza vaccination. All usual medications were continued.

Antimicrobials were ceased after 2 days, with negative bacterial cultures, and the patient started taking 50 mg of prednisolone, tapered over several weeks. He experienced a rapid resolution of fever and progressive normalisation of eosinophilia and neutrophilia (Box 2). Renal function returned to baseline by Day 5 and his rash resolved by Day 7, with the emergence of mild skin desquamation during rash resolution. He remains well 4 months later.

Discussion

DRESS is an uncommon, but potentially life-threatening, drug-induced hypersensitivity reaction, with onset usually 2–8 weeks after exposure to the culprit agent. The pathophysiology of DRESS remains unclear, but it involves an aberrant T-lymphocyte response to an antigen, including drugs and infection.

Influenza infection is associated with significant morbidity and mortality, especially in patients at the extremes of age. Since 2018, high dose or adjuvanted influenza vaccination has been recommended in Australia for individuals aged over 65 years. Flud is an adjuvanted TIV that contains MF59 — an oil-in-water emulsion of squalene (by Novartis) that enhances the cellular and humoral immunogenicity of the vaccine.² This results in higher antibody responses than non-adjuvanted vaccines and improved influenza prevention, while maintaining similar safety in older people.³

As an immune stimulant, it makes sense that vaccination could trigger DRESS in certain individuals. Indeed, DRESS following non-adjuvanted influenza vaccination has been described and may occur early (< 1 week) after vaccine exposure.^{4,5}

In this patient, the strong temporal relationship between vaccination, onset of symptoms and the absence of an alternative trigger suggests a role for adjuvanted TIV as a precipitant of DRESS (Naranjo score 5, classified as probable⁶). While the mechanism is unclear, we hypothesise this could be a direct reaction to a vaccine component, or that non-specific immune activation following vaccination could permit a reaction to a medication, as postulated in previous cases in which each individual was coprescribed a drug typically associated with DRESS (allopurinol⁴ and sulfasalazine⁵). None of our patient's medications are commonly associated with DRESS, although case reports exist. Alternatively, the vaccine response could facilitate reactivation of latent herpes viruses, as these have been implicated in the pathogenesis of DRESS and have been included in some diagnostic criteria.⁷

Nevertheless, influenza vaccination is an unusual precipitant of DRESS. Eosinophilic drug reactions following influenza vaccination are rare,⁸ and large observational studies of adjuvanted TIV given to older individuals have not reported cases of DRESS.^{9,10}

DRESS is an important differential diagnosis in patients presenting with fever and rash. Diagnosis requires a careful history for precipitants, examination for typical features, and investigation to exclude differentials, including infection. While several

medications are classically implicated in the pathophysiology of DRESS, rare reports following vaccination are documented. The management of DRESS includes withdrawal of the causative agent, appropriate supportive care (such as fluids and analgesia), and corticosteroids; patients frequently require hospital admission. Overall, influenza vaccination remains a safe and effective means by which to reduce morbidity and mortality in older individuals.

Lessons from practice

- A drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, potentially life-threatening condition and an important differential diagnosis in patients with fever, extensive morbilliform or purpuric rash, lymphadenopathy and/or facial oedema. Medication changes in the preceding 2–8 weeks should raise the suspicion for DRESS.
 - A diagnosis of DRESS can be made using the RegiSCAR scoring system, which involves examination of the blood and blood film, renal and liver function, skin biopsy, and exclusion of alternative, infective aetiologies. Herpes virus polymerase chain reaction on blood may be a useful adjunct to diagnosis.
 - Treatment of DRESS involves cessation of the culprit drug, supportive care, and a weaning course of steroids.
 - Enhanced trivalent influenza vaccines are currently recommended for all individuals aged over 65 years in Australia. Vaccination remains a safe and effective means to reduce morbidity and mortality associated with influenza infection.
-

Acknowledgements: We acknowledge the input of Jason Trubiano and Nigel Crawford for valuable discussions in the management of this case.

Competing interests: No relevant disclosures.

Provenance: Not commissioned; externally peer reviewed.

Author details

David WJ Griffin^{*,1}

Genevieve E Martin^{*,1}

Catriona McLean¹

Allen C Cheng^{1,2}

Michelle L Giles^{1,2}

¹ Alfred Health, Melbourne, VIC.

² Monash University, Melbourne, VIC.

*** Equal first authors.**

g.martin@alfred.org.au

References

1. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? *Br J Dermatol* 2007; 156: 609-611.
2. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 — an innately attractive adjuvant formulation. *Vaccine* 2012; 30: 4341-4348.
3. Schaffner W, Chen WH, Hopkins RH, Neuzil K. Effective immunization of older adults against seasonal influenza. *Am J Med* 2018; 131: 865-873.
4. Solak B, Dikicier BS, Kara RO, Erdem T. DRESS syndrome potentially induced by allopurinol and triggered by influenza vaccine. *BMJ Case Rep* 2016; 2016: bcr2016214563.
5. Hewitt N, Levinson M, Stephenson G. Drug reaction with eosinophilia and systemic symptoms associated with H1N1 vaccination. *Intern Med J* 2012; 42: 1365-1366.
6. Naranzo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981; 30: 239-245.
7. Shiohara T. The role of viral infection in the development of severe drug eruptions. *Dermatologica Sinica* 2013; 31: 205-210.
8. Ramirez E, Medrano-Casique N, Tong HY, et al. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. *Br J Clin Pharmacol* 2017; 83: 400-415.
9. Villa M, Black S, Groth N, et al. Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. *Am J Epidemiol* 2013; 178: 1139-1145.
10. Lindert K, Leav B, Heijnen E, et al. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older. *Int J Infect Dis* 2019; 85S: S10-S17.

[Insert boxes]

[Box 1; mar_mja19.00709_gr1]

1 Images of the rash on presentation to hospital, as seen over the abdomen and arm, showing a violaceous, purpuric, patchy skin eruption with areas of confluence

[Box 2; mar_mja19.00709_gr2]

2 Eosinophils, neutrophils and total white cell count (WCC) since time of presentation and after the initiation of steroids

[Box 3; mar_mja19.00709_gr3]

3 Haematoxylin and eosin staining of skin biopsy sample (magnification × 200 actual) showing a dermal inflammatory cell infiltrate of lymphocytes and scattered eosinophils with minimal dermal oedema, consistent with a drug reaction. There was no specific immunofluorescence staining or features of vasculitis (not shown)

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Griffin, DWJ;Martin, GE;McLean, C;Cheng, AC;Giles, ML

Title:

A case of drug reaction with eosinophilia and systemic symptoms (DRESS) without a typical precipitant

Date:

2020-02-24

Citation:

Griffin, D. W. J., Martin, G. E., McLean, C., Cheng, A. C. & Giles, M. L. (2020). A case of drug reaction with eosinophilia and systemic symptoms (DRESS) without a typical precipitant. MEDICAL JOURNAL OF AUSTRALIA, 212 (7), pp.300-+. <https://doi.org/10.5694/mja2.50519>.

Persistent Link:

<http://hdl.handle.net/11343/275455>